

REGISTERED COMPANY NUMBER: 08082786 (England and Wales)  
REGISTERED CHARITY NUMBER: 1150234

**REPORT OF THE TRUSTEES AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023  
FOR  
BRITISH NUCLEAR MEDICINE SOCIETY**

E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

**BRITISH NUCLEAR MEDICINE SOCIETY**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	<b>Page</b>
<b>Report of the Trustees</b>	<b>1 to 3</b>
<b>Independent Examiner's Report</b>	<b>4</b>
<b>Statement of Financial Activities</b>	<b>5</b>
<b>Balance Sheet</b>	<b>6</b>
<b>Cash Flow Statement</b>	<b>7</b>
<b>Notes to the Cash Flow Statement</b>	<b>8</b>
<b>Notes to the Financial Statements</b>	<b>9 to 14</b>
<b>Detailed Statement of Financial Activities</b>	<b>15 to 16</b>

# **BRITISH NUCLEAR MEDICINE SOCIETY**

## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

### **OBJECTIVES AND ACTIVITIES**

#### **Objectives and aims**

British Nuclear Medicine Society is dedicated to promoting the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

The specific objectives of the British Nuclear Medicine Society are to:

- 1 Raise the profile of nuclear medicine
- 2 Engage with all health care providers involved in the clinical use of radionuclides
- 3 Provide a forum for the communication of advances in nuclear medicine
- 4 Provide resources and encourage the provision of education and training to support continuing professional development.
- 5 Represent nuclear medicine with official bodies and on advisory committees
- 6 Develop and promote standards and guidelines for the safe and effective practice of nuclear medicine
- 7 Promote nuclear medicine research and development
- 8 Improve the level of support to isolated departments
- 9 Provide greater information for the benefit of patients
- 10 Promote and support the recertification/revalidation of practitioners
- 11 Maintain an appropriate charitable status.

#### **Significant activities**

In order for the charity to achieve its aim BNMS engage in the following activities:

- Raising the profile of nuclear medicine through the website, scientific meetings and attendance of careers fairs.
- Engaging with other professional organisations, including British Institute of Radiology, British Cardiology Society, Institute of Physics and Engineering in Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Surgeons, Royal College of Nursing, Society and College of Radiographers and Society of Radiological Protection.
- Providing a forum for the communication of advances in nuclear medicine through annual and regional scientific meetings, Nuclear Medicine Communications (the official BNMS journal) and the BNMS website.
- Leading in the provision of education and training to support the development of nuclear medicine
- Representing the specialty on relevant official bodies and advisory committees
- Developing and promoting standards and guidelines for the safe practice of nuclear medicine.
- Promoting nuclear medicine research and development by engaging with academic institutions and industry to promote research leading to new developments and improvements in clinical practice.

#### **Public benefit**

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

# BRITISH NUCLEAR MEDICINE SOCIETY

## REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023

### ACHIEVEMENT AND PERFORMANCE

#### Charitable activities

The British Nuclear Medicine Society held three scientific and educational meetings this year around the UK, the results of which are as follows:

	Spring Harrogate £	Autumn London £	Online Educational £	Total £
<b>Income</b>				
Commercial exhibition income	159,973	26,048	1,000	187,021
Annual conference delegate registration fees	105,468	25,466	17,546	148,480
	<hr/>	<hr/>	<hr/>	<hr/>
	265,441	51,514	18,546	335,501
Less: Scientific meeting expenses	187,789	43,683	7,135	238,607
	<hr/>	<hr/>	<hr/>	<hr/>
Surplus	77,652	7,831	11,411	96,894
	<hr/>	<hr/>	<hr/>	<hr/>

#### Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

### FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

### STRUCTURE, GOVERNANCE AND MANAGEMENT

#### Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

### REFERENCE AND ADMINISTRATIVE DETAILS

#### Registered Company number

08082786 (England and Wales)

#### Registered Charity number

1150234

#### Registered office

Royal College of Physicians  
11 St Andrews Place  
Regents Park  
London  
NW1 4LE

#### Trustees

Who are also directors

Mrs J Croasdale

Dr R Graham

Dr S Redman

Dr J R Buscombe (Resigned 17 May 22)

Mr C S Kalirai (appointed 17 May 22)

Radiopharmacist

Radiologist

Radiologist

Nuclear Medicine Physician

Clinical Scientist

#### Independent Examiner

E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

Approved by order of the board of trustees on 8 May 2024 and signed on its behalf by:

**BRITISH NUCLEAR MEDICINE SOCIETY**  
**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

Mr C S Kalirai - Trustee

## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY**

### **Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

### **Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

### **Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited  
Grove House  
Coombs Wood Court  
Steel Park Road  
Halesowen  
West Midlands  
B62 8BF

8 May 2024

**BRITISH NUCLEAR MEDICINE SOCIETY**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	Unrestricted fund £	Restricted fund £	2023 Total funds £	2022 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	2	4,400	-	4,400	3,500
Other trading activities	3	412,849	(83)	412,766	319,943
Investment income	4	5,768	165	5,933	1,706
Other income		90,564	-	90,564	64,036
<b>Total</b>		<u>513,581</u>	<u>82</u>	<u>513,663</u>	<u>389,185</u>
<b>EXPENDITURE ON</b>					
Raising funds	5	422,080	217	422,297	339,483
<b>NET INCOME/(EXPENDITURE)</b>		91,501	(135)	91,366	49,702
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		390,382	14,408	404,790	355,088
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>

The notes form part of these financial statements

# BRITISH NUCLEAR MEDICINE SOCIETY

## BALANCE SHEET 31 DECEMBER 2023

	Notes	Unrestricted fund £	Restricted fund £	2023 Total funds £	2022 Total funds £
<b>FIXED ASSETS</b>					
Tangible assets	11	2,415	-	2,415	3,129
<b>CURRENT ASSETS</b>					
Debtors	12	168,525	-	168,525	189,273
Cash at bank		418,872	14,273	433,145	346,722
		<u>587,397</u>	<u>14,273</u>	<u>601,670</u>	<u>535,995</u>
<b>CREDITORS</b>					
Amounts falling due within one year	13	(107,929)	-	(107,929)	(134,334)
<b>NET CURRENT ASSETS</b>		<u>479,468</u>	<u>14,273</u>	<u>493,741</u>	<u>401,661</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
<b>NET ASSETS</b>		<u>481,883</u>	<u>14,273</u>	<u>496,156</u>	<u>404,790</u>
<b>FUNDS</b>	14				
Unrestricted funds				481,883	390,382
Restricted funds				14,273	14,408
<b>TOTAL FUNDS</b>				<u>496,156</u>	<u>404,790</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 8 May 2024 and were signed on its behalf by:

Mr C S Kalirai - Trustee

**BRITISH NUCLEAR MEDICINE SOCIETY**

**CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	2023 £	2022 £
<b>Cash flows from operating activities</b>			
Cash generated from operations	1	80,923	90,998
		<hr/>	<hr/>
Net cash provided by operating activities		80,923	90,998
		<hr/>	<hr/>
<b>Cash flows from investing activities</b>			
Purchase of tangible fixed assets		(433)	-
Interest received		5,933	1,706
		<hr/>	<hr/>
Net cash provided by investing activities		5,500	1,706
		<hr/>	<hr/>
<b>Change in cash and cash equivalents in the reporting period</b>		86,423	92,704
<b>Cash and cash equivalents at the beginning of the reporting period</b>		346,722	254,018
		<hr/>	<hr/>
<b>Cash and cash equivalents at the end of the reporting period</b>		433,145	346,722
		<hr/> <hr/>	<hr/> <hr/>

The notes form part of these financial statements

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE CASH FLOW STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	2023 £	2022 £
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	91,366	49,702
<b>Adjustments for:</b>		
Depreciation charges	1,147	1,494
Interest received	(5,933)	(1,706)
Decrease in debtors	20,748	14,638
(Decrease)/increase in creditors	(26,405)	26,870
<b>Net cash provided by operations</b>	<u>80,923</u>	<u>90,998</u>

**2. ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.23 £	Cash flow £	At 31.12.23 £
<b>Net cash</b>			
Cash at bank	346,722	86,423	433,145
	<u>346,722</u>	<u>86,423</u>	<u>433,145</u>
<b>Total</b>	<u>346,722</u>	<u>86,423</u>	<u>433,145</u>

The notes form part of these financial statements

# BRITISH NUCLEAR MEDICINE SOCIETY

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

### 1. ACCOUNTING POLICIES

#### **Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

#### **Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

#### **Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expense are recognised in the Statement of Financial Activities in the year that the exhibition is held.

#### **Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 15% on reducing balance
Computer equipment	- 33% on reducing balance

#### **Taxation**

The charity is exempt from corporation tax on its charitable activities.

#### **Fund accounting**

Unrestricted funds are available of use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

#### **Pension costs and other post-retirement benefits**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**2. DONATIONS AND LEGACIES**

	2023	2022
	£	£
Donations	<u>4,400</u>	<u>3,500</u>

**3. OTHER TRADING ACTIVITIES**

	2023	2022
	£	£
Commercial exhibition income	187,021	148,658
Annual conference delegate registration fees	148,480	98,356
Commission received	4,124	169
Royalties received	71,861	72,760
Other project income	1,280	-
	<u>412,766</u>	<u>319,943</u>

**4. INVESTMENT INCOME**

	2023	2022
	£	£
Deposit account interest	<u>5,933</u>	<u>1,706</u>

**5. RAISING FUNDS**

**Raising donations and legacies**

	2023	2022
	£	£
Support costs	<u>141,820</u>	<u>106,165</u>

**Other trading activities**

	2023	2022
	£	£
Purchases	239,557	189,112
Awards and prizes	1,432	775
Journal subscriptions	39,488	43,431
	<u>280,477</u>	<u>233,318</u>
Aggregate amounts	<u>422,297</u>	<u>339,483</u>

**6. SUPPORT COSTS**

	Management	Finance	Other	Governance	Totals
	£	£	£	costs £	£
Raising donations and legacies	<u>133,668</u>	<u>2,934</u>	<u>1,147</u>	<u>4,071</u>	<u>141,820</u>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**7. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2023	2022
	£	£
Other assurance services	3,831	4,383
Depreciation - owned assets	<u>1,146</u>	<u>1,494</u>

**8. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

**Trustees' expenses**

Payments totalling £4,761 (2022: £1,645) were made to trustees to reimburse travel costs to conferences and council meetings.

**9. STAFF COSTS**

	2023	2022
	£	£
Wages and salaries	86,558	65,168
Other pension costs	<u>3,079</u>	<u>2,947</u>
	<u>89,637</u>	<u>68,115</u>

The average monthly number of employees during the year was as follows:

	2023	2022
Administrative	<u>3</u>	<u>2</u>

No employees received emoluments in excess of £60,000.

**10. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	3,500	-	3,500
Other trading activities	319,943	-	319,943
Investment income	1,666	40	1,706
Other income	<u>64,036</u>	<u>-</u>	<u>64,036</u>
<b>Total</b>	<u>389,145</u>	<u>40</u>	<u>389,185</u>
<b>EXPENDITURE ON</b>			
Raising funds	<u>339,483</u>	<u>-</u>	<u>339,483</u>
<b>NET INCOME</b>	49,662	40	49,702
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	<u>340,720</u>	<u>14,368</u>	<u>355,088</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>390,382</u>	<u>14,408</u>	<u>404,790</u>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**11. TANGIBLE FIXED ASSETS**

	Fixtures and fittings £	Computer equipment £	Totals £
<b>COST</b>			
At 1 January 2023	905	30,102	31,007
Additions	-	432	432
At 31 December 2023	905	30,534	31,439
<b>DEPRECIATION</b>			
At 1 January 2023	685	27,193	27,878
Charge for year	33	1,113	1,146
At 31 December 2023	718	28,306	29,024
<b>NET BOOK VALUE</b>			
At 31 December 2023	187	2,228	2,415
At 31 December 2022	220	2,909	3,129

**12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023 £	2022 £
Trade debtors	49,542	70,732
Other debtors	39,132	40,428
Prepayments and accrued income	79,851	78,113
	168,525	189,273

**13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023 £	2022 £
Trade creditors	4,160	5,897
Social security and other taxes	1,959	2,177
VAT	13,989	20,665
Other creditors	82,440	100,959
Accrued expenses	5,381	4,636
	107,929	134,334

**14. MOVEMENT IN FUNDS**

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
<b>Unrestricted funds</b>			
General fund	390,382	91,501	481,883
<b>Restricted funds</b>			
Ross Breen Fund	14,408	(135)	14,273
<b>TOTAL FUNDS</b>	404,790	91,366	496,156

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**14. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	513,581	(422,080)	91,501
<b>Restricted funds</b>			
Ross Breen Fund	82	(217)	(135)
<b>TOTAL FUNDS</b>	<u>513,663</u>	<u>(422,297)</u>	<u>91,366</u>

**Comparatives for movement in funds**

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
<b>Unrestricted funds</b>			
General fund	340,720	49,662	390,382
<b>Restricted funds</b>			
Ross Breen Fund	14,368	40	14,408
<b>TOTAL FUNDS</b>	<u>355,088</u>	<u>49,702</u>	<u>404,790</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	389,145	(339,483)	49,662
<b>Restricted funds</b>			
Ross Breen Fund	40	-	40
<b>TOTAL FUNDS</b>	<u>389,185</u>	<u>(339,483)</u>	<u>49,702</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.22 £	Net movement in funds £	At 31.12.23 £
<b>Unrestricted funds</b>			
General fund	340,720	141,163	481,883
<b>Restricted funds</b>			
Ross Breen Fund	14,368	(95)	14,273
<b>TOTAL FUNDS</b>	<u>355,088</u>	<u>141,068</u>	<u>496,156</u>

**BRITISH NUCLEAR MEDICINE SOCIETY**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**14. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	902,726	(761,563)	141,163
<b>Restricted funds</b>			
Ross Breen Fund	122	(217)	(95)
<b>TOTAL FUNDS</b>	<u>902,848</u>	<u>(761,780)</u>	<u>141,068</u>

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

**15. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2023.

**BRITISH NUCLEAR MEDICINE SOCIETY**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	2023 £	2022 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	4,400	3,500
<b>Other trading activities</b>		
Commercial exhibition income	187,021	148,658
Annual conference delegate registration fees	148,480	98,356
Commission received	4,124	169
Royalties received	71,861	72,760
Other project income	1,280	-
	<hr/> 412,766	<hr/> 319,943
<b>Investment income</b>		
Deposit account interest	5,933	1,706
<b>Other income</b>		
Members subscriptions	90,564	64,036
	<hr/> 513,663	<hr/> 389,185
<b>Total incoming resources</b>		
<b>EXPENDITURE</b>		
<b>Other trading activities</b>		
Scientific meeting expenses	238,607	183,663
Other project expenses	950	5,449
Awards and prizes	1,432	775
Journal subscriptions	39,488	43,431
	<hr/> 280,477	<hr/> 233,318
<b>Support costs</b>		
<b>Management</b>		
Wages and social security	86,558	65,168
Pensions	3,079	2,947
Rent	1,280	1,265
Insurance	1,033	813
Subscriptions	678	1,332
Telephone	709	517
Postage and stationery	867	615
General meeting and travelling expenses	19,711	7,051
Sundries	355	113
Computer costs	19,398	16,493
Advertising and website costs	-	796
	<hr/> 133,668	<hr/> 97,110
<b>Finance</b>		
Bank charges	1,681	1,419
Direct debit processing costs	1,253	1,069
	<hr/> 2,934	<hr/> 2,488
<b>Other</b>		
Fixtures and fittings	33	39
Carried forward	33	39

This page does not form part of the statutory financial statements

**BRITISH NUCLEAR MEDICINE SOCIETY**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	2023 £	2022 £
<b>Other</b>		
Brought forward	33	39
Computer equipment	1,114	1,455
	<hr/> 1,147	<hr/> 1,494
<b>Governance costs</b>		
Auditors' remuneration for non audit work	3,831	4,383
Professional charges	-	450
Payroll costs	240	240
	<hr/> 4,071	<hr/> 5,073
Total resources expended	<hr/> 422,297	<hr/> 339,483
<b>Net income</b>	<hr/> <hr/> 91,366	<hr/> <hr/> 49,702

This page does not form part of the statutory financial statements